Bellicum Pharmaceuticals, Inc. Is focused primarily on the development of next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer.

Founded by Baylor College of Medicine Professors Kevin M. Slawin, M.D. and David M. Spencer, Ph.D., the Company plans to produce clinical products based on novel and powerful vaccine strategies developed by renowned Baylor College of Medicine researchers that have the potential to enhance the efficacy of therapeutic vaccines against important diseases.

Bellicum's first product, BP-GMAX-CD1, is a genetically-modified autologous cell-based vaccine that is in late stage preclinical development.